Published in J Immunol Methods on November 19, 1999
Estimating the precursor frequency of naive antigen-specific CD8 T cells. J Exp Med (2002) 5.16
Early block to erythromegakaryocytic development conferred by loss of transcription factor GATA-1. Blood (2005) 1.72
Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother (2011) 1.41
Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle (2012) 1.41
Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. J Immunol Methods (2010) 1.35
A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med (2013) 1.32
Numerical modelling of label-structured cell population growth using CFSE distribution data. Theor Biol Med Model (2007) 1.25
T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med (2005) 1.24
Staphylococcal superantigens in colonization and disease. Front Cell Infect Microbiol (2012) 1.15
A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res (2010) 1.05
Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol (2007) 1.03
New methods for assessing T-cell responses. Clin Diagn Lab Immunol (2000) 1.00
Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). J Mol Med (Berl) (2010) 0.97
Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells. Vaccine (2008) 0.92
Evaluation of CD4+ T cells proliferating to grass pollen in seasonal allergic subjects by flow cytometry. Clin Exp Immunol (2003) 0.90
Tracking immune cell proliferation and cytotoxic potential using flow cytometry. Methods Mol Biol (2011) 0.88
Detection of cellular immunity to rabies antigens in human vaccinees. J Clin Immunol (2006) 0.81
Self-reactive CD4+ T cells and B cells in the blood in health and autoimmune disease: increased frequency of thyroglobulin-reactive cells in Graves' disease. J Clin Immunol (2006) 0.80
Differences amid bone marrow and cord blood hematopoietic stem/progenitor cell division kinetics. J Cell Physiol (2009) 0.77
Glutathione-mediated antioxidant response and aerobic metabolism: two crucial factors involved in determining the multi-drug resistance of high-risk neuroblastoma. Oncotarget (2016) 0.77
Detailed kinetics of the direct allo-response in human liver transplant recipients: new insights from an optimized assay. PLoS One (2010) 0.76
The retinoic acid receptor-α modulators ATRA and Ro415253 reciprocally regulate human IL-5+ Th2 cell proliferation and cytokine expression. Clin Mol Allergy (2013) 0.76
Functional Modulation of Regulatory T Cells by IL-2. PLoS One (2015) 0.75
PI3K/Akt/mTOR signaling and plasma membrane proteins are implicated in responsiveness to adjuvant dendritic cell vaccination for metastatic colorectal cancer. Clin Cancer Res (2016) 0.75
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Signal transduction cascades regulating fungal development and virulence. Microbiol Mol Biol Rev (2000) 5.49
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Using empowerment theory in collaborative partnerships for community health and development. Am J Community Psychol (1995) 3.16
Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2000) 2.37
Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br J Dermatol (2012) 2.20
Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine (2000) 2.18
Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol (1996) 2.06
Hepatitis B antigen and antibody in a male homosexual population. Br J Vener Dis (1977) 1.98
Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58
Syphilis as a cause of backache. Br Med J (1972) 1.55
Sexually transmitted diseases and prostitution. J R Soc Med (1989) 1.52
High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst (1990) 1.51
Status dystonicus and Hallervorden-Spatz disease: treatment with intrathecal baclofen and pallidotomy. J Paediatr Child Health (2004) 1.45
Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons. Ann N Y Acad Sci (1999) 1.36
Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. J Immunol (1992) 1.31
SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J Neurooncol (2001) 1.23
In vivo description of dendritic cells in human renal cell carcinoma. J Urol (1999) 1.23
Interferons in the treatment of human cancer. J Clin Oncol (1984) 1.22
Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery (2001) 1.20
Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma. Cytotherapy (2006) 1.11
Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology (1997) 1.08
Regulation of human monocyte HLA-DR and CD4 antigen expression, and antigen presentation by 1,25-dihydroxyvitamin D3. Blood (1990) 1.06
Conscious sedation or general anaesthetic for intramuscular botulinum toxin injections in children - a two centre cross-sectional prospective audit. Eur J Paediatr Neurol (2011) 1.06
Virus-like particles associated with a faecal antigen from hepatitis patients and with Australia antigen. Aust J Exp Biol Med Sci (1971) 1.05
Increased potency of Fc-receptor-targeted antigens. Cancer Immunol Immunother (1998) 1.03
Spontaneous and gamma-aminobutyric acid (GABA)-activated GABA(A) receptor channels formed by epsilon subunit-containing isoforms. Mol Pharmacol (1999) 1.03
Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer (2001) 1.00
Demographic and phenotypic features of 70 families segregating Barrett's oesophagus and oesophageal adenocarcinoma. J Med Genet (2003) 1.00
Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med (1985) 0.98
Methodological considerations for implementation of lymphocyte subset analysis in a clinical reference laboratory. Ann N Y Acad Sci (1986) 0.97
Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. J Immunol Methods (2001) 0.94
A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res (1985) 0.94
Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis (1999) 0.94
An analysis of interobserver recognition of the histopathologic features of dysplastic nevi from a mixed group of nevomelanocytic lesions. J Am Acad Dermatol (1992) 0.93
Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J Immunother Emphasis Tumor Immunol (1993) 0.93
Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood. J Immunol (1998) 0.93
Immunohistochemical localization of metallothionein in transitional cell carcinoma of the bladder. J Urol (1991) 0.92
Prevalence of chronic respiratory symptoms among Ohio cash grain farmers. Am J Ind Med (1999) 0.92
Child Sexual Behavior Inventory: normative, psychiatric, and sexual abuse comparisons. Child Maltreat (2001) 0.92
Recruitment of myeloid and plasmacytoid dendritic cells in cervical mucosa during Chlamydia trachomatis infection. Clin Microbiol Infect (2008) 0.91
Experimental strain analysis of infant, adolescent and adult miniature swine skulls subjected to timulated mastication forces. J Biomech (1976) 0.91
Effects of a replication of a multicomponent model for preventing adolescent pregnancy in three Kansas communities. Fam Plann Perspect (1999) 0.90
Condylomata acuminata. Br Med J (1972) 0.90
Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol (1995) 0.89
Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res (1998) 0.89
Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res (1995) 0.88
Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018). J Clin Oncol (1987) 0.87
The Genome Sequence DataBase (GSDB): improving data quality and data access. Nucleic Acids Res (1998) 0.87
Bispecific-armed, interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma. Blood (1996) 0.87
Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin for locally advanced transitional cell carcinoma of the bladder. Cancer (1990) 0.86
Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. Breast Cancer Res Treat (1999) 0.86
Loss of heterozygosity on chromosome 11q22-23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase-1 promoter. Am J Pathol (2001) 0.86
Longitudinal relationship of early life immunomodulatory T cell phenotype and function to development of allergic sensitization in an urban cohort. Clin Exp Allergy (2011) 0.86
Sonographic characteristics of epidermoid cyst of testicle. Urology (1990) 0.85
Dysplastic nevus in histologic contiguity with acquired nonfamilial melanoma. Clinicopathologic experience in a 100-bed hospital. Arch Dermatol (1987) 0.85
Dysplastic nevi in association with multiple primary melanoma. Cancer Res (1988) 0.83
Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma. Bone Marrow Transplant (2007) 0.83
Improvements in GORE-TEX vascular graft performance by Carmeda BioActive surface heparin immobilization. Eur J Vasc Endovasc Surg (2003) 0.83
Selective modulation of IFN-gamma mRNA stability by IL-12/NKSF. Cell Immunol (1994) 0.83
Role of interferons in the therapy of melanoma. J Invest Dermatol (1990) 0.83
Fast JPDA multitarget tracking algorithm. Appl Opt (1989) 0.83
Castanospermine blocks the hyperglycemic response to carbohydrates in vivo: a result of intestinal disaccharidase inhibition. Life Sci (1987) 0.83
High resolution brain SPECT imaging of marijuana smokers with AD/HD. J Psychoactive Drugs (1998) 0.83
Inter-clinician agreement on the recognition of clinical pigmentary characteristics of patients with cutaneous malignant melanoma. Studies of melanocytic nevi, VI. Br J Cancer (1991) 0.82
The major gangliosides of human peripheral blood monocytes/macrophages: absence of ganglio series structures. Glycobiology (2001) 0.82
T-cell receptor zeta-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma. Cancer Res (1997) 0.82
Presurgical serum albumin levels predict survival time from glioblastoma multiforme. J Neurooncol (1999) 0.81
Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield. The Tissue Bank, Pittsburgh Cancer Institute. Melanoma Res (1993) 0.81
A relation between childhood sun exposure and dysplastic nevus syndrome among patients with nonfamilial melanoma. Epidemiology (1991) 0.81
HIV-1-infected monocytes and monocyte-derived macrophages are impaired in their ability to produce superoxide radicals. Int J Clin Lab Res (1997) 0.81
DNA analysis of multiple synchronous renal cell carcinomas. Cancer (1990) 0.81
Subcellular localization of metallothionein IIA in human bladder tumor cells using a novel epitope-specific antiserum. Toxicol Appl Pharmacol (1994) 0.80
Characteristics and outcome of children with carbon monoxide poisoning with and without smoke exposure referred for hyperbaric oxygen therapy. Pediatr Emerg Care (2000) 0.80
Increased attractiveness of man to mosquitoes with induced eccrine sweating. Nature (1969) 0.80
Optimizing the detection of cell surface antigens on elicited or activated mouse peritoneal macrophages. Cytometry (1994) 0.80
Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. J Immunol Methods (2001) 0.80
Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells. Cancer Res (1997) 0.79
Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. Am J Med (1984) 0.79
Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu. J Immunother (2001) 0.79
Fluorouracil, interferon-alpha, and colon cancer: rational pursuit of synergism between antimetabolites and biologicals. J Clin Oncol (1989) 0.78
Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: case report and review of the literature. Leuk Lymphoma (2005) 0.78
Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials. J Biol Response Mod (1983) 0.78
Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo. J Immunol Methods (2001) 0.78
Effect of social drinking on neuropsychological performance. Br J Addict (1989) 0.78
Inflammatory cell infiltrate in a responding metastatic nodule after vaccine-based immunotherapy. Clin Exp Immunol (1998) 0.78
In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma. J Clin Oncol (1990) 0.78
Comparison of nonfamilial and familial melanoma. Dermatology (1992) 0.78
Hypotheses concerning roles of dietary energy, cured meat, and serum tocopherols in adult glioma development. Neuroepidemiology (1999) 0.78
Taxanes synergize with the bispecific antibody MDXH447 to enhance antibody-dependent cell-mediated cytotoxicity. J Chemother (2003) 0.78
Evaluating community initiatives for health and development. WHO Reg Publ Eur Ser (2001) 0.78
Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study. J Urol (1995) 0.78
Differential effect of cytokine treatment on Fc alpha receptor I- and Fc gamma receptor I-mediated tumor cytotoxicity by monocyte-derived macrophages. J Immunol (2000) 0.78